Fulminant acute hepatitis B after infliximab treatment in Crohn's disease
Olfa, H.; Aroua, G.; Wissem, M.; Wafa, B.M.; Hichem, L.; Nabil, B.C.èn.; Fethia, B.; Leila, S.
La Tunisie Medicale 92(5): 349-350
2014
ISSN/ISBN: 0041-4131 PMID: 25504398 Document Number: 675573
Document emailed within 1 workday
Related Documents
Zheng, J.-J.; Wang, Y.-M.; Zhu, F.; Gu, W.; Xing, Y.-C.; Zhou, C.-L.; Shen, B.-W. 2009: A study of efficiacy of infliximab treatment for Crohn's disease Zhonghua Nei Ke Za Zhi 48(11): 922-925Yang, B.-l.; Lin, Q.; Chen, H.-j.; Sun, G.-d.; Zhu, P.; Chen, Y.-q.; Gu, Y.-f. 2013: Efficacy of infliximab combined with surgery in the treatment of perianal fistulizing Crohn disease Zhonghua Wei Chang Wai Ke Za Zhi 16(4): 323-327
Famenini, S.; Wu, J.J. 2013: Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases Journal of Drugs in Dermatology: Jdd 12(8): 939-943
Hartleb, M.; Zahorska-Markiewicz, B.; Bołdys, H.; Kucio, C.; Siemaszko, M. 1986: Fulminant hepatitis and acute hemolysis as the symptoms of Wilson's disease Polski Tygodnik Lekarski 41(17): 559-561
Smits, S.R.J.G.; Heijman, J.A.; van Dullemen, H.M.; Rutten, W.J.M.J.; Annemans, L.; Brouwers, J.R.B.J.; Postma, M.J. 2002: Treatment with infliximab in patients with Crohn disease; experience in 132 patients Nederlands Tijdschrift Voor Geneeskunde 146(39): 1857-8; author reply 1858
Sinagra, E.; Orlando, A.; Renna, S.; Criscuoli, V.; La Seta, F.; Olivo, M.; Ciofalo, M.; Cottone, M. 2013: Is really megacolon a contraindication to infliximab in Crohn's disease? Acta Gastro-Enterologica Belgica 76(4): 442-444
Arslan, S.; Kav, T.; Besisik, F.; Kaymakoglu, S.; Pinarbasi, B.; Tözün, N.; Hamzaoglu, Hülya.Over.; Duman, D.; Ulker, A.; Parlak, E.; Palabiyikoglu, M.; Dökmeci, Aülkadir. 2003: Clinical outcome of Crohn's disease treated with infliximab Hepato-Gastroenterology 50(52): 952-956
Ngo, M.D.; Hagège, H.; Rosa, I.; Cartier, V.A.; Lons, T.; Gordin, J.; Chousterman, M. 1999: Acute hepatitis in the course of cyclosporine therapy of Crohn's disease Presse Medicale 28(34): 1873-1875
Luna-Chadid, M.; Pérez Calle, J.L.; Mendoza, J.L.; Vera, M.I.; Bermejo, A.F.; Sánchez, F.; López San Román, A.; Froilán, C.; González-Lara, V.; García-Paredes, J.; Fernández-Blanco, I.; Abreu, L.; Casis, B.; Solís Herruzo, J.A.; Gisbert, J.P.; Maté Jiménez, J. 2004: Predictors of response to infliximab in patients with fistulizing Crohn's disease Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 96(6): 379-81; 382-4
Gerolami, R.; Mambrini, P.; Barthet, M.; Jean-Pastor, M.J.; Salducci, J.; Grimaud, J.C. 1997: Acute hepatitis caused by Solupred in a patient with Crohn disease Gastroenterologie Clinique et Biologique 21(3): 236-237
Ferkolj, I.; Ihan, A.; Markovic, S. 2005: CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease Hepato-Gastroenterology 52(64): 1128-1133
Cadahia, V.; García-Carbonero, A.; Vivas, S.; Fuentes, D.; Niño, P.; Rebollo, P.; Rodrigo, L. 2004: Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 96(6): 369-74; 374-8
Bretagne, J.F.; Raoul, J.L.; Siproudhis, L.; Cado, J.P.; Gosselin, M. 1991: Successful treatment of fulminant Crohn's colitis with azathioprine Gastroenterologie Clinique et Biologique 15(8-9): 654-655
Herman, R.; Sładek, M.łg.; Pieczarkowski, S.ła.; Dumnicka, P.; Fyderek, K. 2017: Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn's disease? Folia Medica Cracoviensia 57(2): 63-71
Sacco, R.; Bertini, M.; Bresci, G.; Romano, A.; Altomare, E.; Capria, A. 2010: Entecavir for hepatitis B virus flare treatment in patients with Crohn's disease Hepato-Gastroenterology 57(98): 242-245
Danese, S.; Sans, M.; Scaldaferri, F.; Sgambato, A.; Rutella, S.; Cittadini, A.; Piqué, J.M.; Panes, J.; Katz, J.A.; Gasbarrini, A.; Fiocchi, C. 2006: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease Journal of Immunology 176(4): 2617-2624
Shikata, T. 1973: Fulminant form of acute and sub-acute hepatitis: its concepts and pathogenesis Nihon Rinsho. Japanese Journal of Clinical Medicine 31(10): 2900-2905
Kanda, T.; Yokosuka, O.; Hiraide, A.; Kojima, H.; Honda, A.; Fukai, K.; Imazeki, F.; Nagao, K.; Saisho, H. 2005: Prevalence of obesity in patients with acute hepatitis; is severe obesity a risk factor for fulminant hepatitis in Japan? Hepato-Gastroenterology 52(61): 180-182
Sheinbaum, A.J.; Damus, K.H.; Michael, T.D.; Gitnick, G.L. 1974: Acute fulminant hepatitis. a clustering of cases Archives of Internal Medicine 134(6): 1093-1094
Auer, I.O.; Röder, A.; Mittelstaedt, A. 1985: Treatment of Crohn's disease using Colibiogen. Cellular reactions of the immune system in patients with Crohn's disease Fortschritte der Medizin 103(46): 1076-1080